An inactivated cell culture Japanese encephalitis vaccine (JEADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody

Petrovsky, Nikolai, Larena, Maximilian, Siddharthan, Venkatraman, Prow, Natalie A., Hall, Roy A., Lobigs, Mario and Morrey, John (2013) An inactivated cell culture Japanese encephalitis vaccine (JEADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. Journal of Virology, 87 18: 10324-10333. doi:10.1128/JVI.00480-13


Author Petrovsky, Nikolai
Larena, Maximilian
Siddharthan, Venkatraman
Prow, Natalie A.
Hall, Roy A.
Lobigs, Mario
Morrey, John
Title An inactivated cell culture Japanese encephalitis vaccine (JEADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody
Journal name Journal of Virology   Check publisher's open access policy
ISSN 0022-538X
1098-5514
1070-6321
Publication date 2013-09-15
Year available 2013
Sub-type Article (original research)
DOI 10.1128/JVI.00480-13
Open Access Status DOI
Volume 87
Issue 18
Start page 10324
End page 10333
Total pages 10
Place of publication Washington, DC, United States
Publisher American Society for Microbiology
Collection year 2014
Language eng
Formatted abstract
West Nile virus (WNV), currently the cause of a serious U.S. epidemic, is a mosquito-borne flavivirus and member of the Japanese encephalitis (JE) serocomplex. There is currently no approved human WNV vaccine, and treatment options remain limited, resulting in significant mortality and morbidity from human infection. Given the availability of approved human JE vaccines, this study asked whether the JE-ADVAX vaccine, which contains an inactivated cell culture JE virus antigen formulated with Advax delta inulin adjuvant, could provide heterologous protection against WNV infection in wild-type and β2-microglobulin-deficient (β2m−/−) murine models. Mice immunized twice or even once with JE-ADVAX were protected against lethal WNV challenge even when mice had low or absent serum cross-neutralizing WNV titers prior to challenge. Similarly, β2m−/− mice immunized with JE-ADVAX were protected against lethal WNV challenge in the absence of CD8+ T cells and prechallenge WNV antibody titers. Protection against WNV could be adoptively transferred to naive mice by memory B cells from JE-ADVAX-immunized animals. Hence, in addition to increasing serum cross-neutralizing antibody titers, JE-ADVAX induced a memory B-cell population able to provide heterologous protection against WNV challenge. Heterologous protection was reduced when JE vaccine antigen was administered alone without Advax, confirming the importance of the adjuvant to induction of cross-protective immunity. In the absence of an approved human WNV vaccine, JE-ADVAX could provide an alternative approach for control of a major human WNV epidemic.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 23 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 27 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 18 Sep 2013, 11:20:28 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences